Federal Circuit again invalidates Cordis patent claims against Medtronic, Abbott, Boston Sci.

June 28, 2013 by Arezu Sarvestani

Johnson & Johnson subsidiary Cordis Corp. and Pfizer subsidiary Wyeth Pharma. fail to reverse a lower court's rulings invalidating patents for drug-eluting coronary stent technology.

Stent Wars logo

A trio of medical device giants notched another win against Johnson & Johnson(NYSE:JNJ) after a Federal Circuit judge upheld a lower court's ruling that invalidated stent patents held by J&J subsidiary Cordis Corp.

Device makers Abbott (NYSE:ABT), Boston Scientific (NYSE:BSX) and Medtronic (NYSE:MDT) cemented their previous win the in long-running battle over drug-eluting stent technology and a coating drug called rapamycin.

Sign up to get our free newsletters delivered right to your inbox.

A 3-member panel of judges for the Federal Circuit ruled this week to invalidate patents held by Cordis and Wyeth Pharmaceuticals, a subsidiary of Pfizer Inc. (NYSE:PFE).